Seer (NASDAQ:SEER) Upgraded at TD Cowen

TD Cowen upgraded shares of Seer (NASDAQ:SEER) to a strong-buy rating in a research report report published on Monday morning,Zacks.com reports.

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Seer in a research report on Thursday, January 22nd. One investment analyst has rated the stock with a Strong Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy”.

Seer Stock Performance

Shares of SEER stock opened at $1.96 on Monday. Seer has a one year low of $1.65 and a one year high of $2.41. The company’s 50-day simple moving average is $1.82 and its 200-day simple moving average is $1.94. The stock has a market capitalization of $110.58 million, a price-to-earnings ratio of -1.53 and a beta of 1.59.

Seer (NASDAQ:SEER) last issued its quarterly earnings results on Thursday, February 26th. The company reported ($0.29) EPS for the quarter, topping the consensus estimate of ($0.32) by $0.03. Seer had a negative net margin of 443.96% and a negative return on equity of 26.04%. The business had revenue of $4.20 million for the quarter, compared to analysts’ expectations of $4.60 million. As a group, research analysts forecast that Seer will post -1.42 EPS for the current year.

Hedge Funds Weigh In On Seer

Several large investors have recently added to or reduced their stakes in the company. Dimensional Fund Advisors LP lifted its stake in Seer by 2.8% during the fourth quarter. Dimensional Fund Advisors LP now owns 235,485 shares of the company’s stock worth $431,000 after purchasing an additional 6,304 shares during the last quarter. Shay Capital LLC lifted its holdings in Seer by 17.7% in the third quarter. Shay Capital LLC now owns 73,571 shares of the company’s stock worth $160,000 after acquiring an additional 11,073 shares during the last quarter. Occudo Quantitative Strategies LP bought a new position in Seer in the second quarter worth about $25,000. Vanguard Group Inc. lifted its holdings in Seer by 0.9% in the third quarter. Vanguard Group Inc. now owns 2,221,404 shares of the company’s stock worth $4,820,000 after acquiring an additional 18,760 shares during the last quarter. Finally, Corient Private Wealth LLC lifted its holdings in Seer by 46.3% in the second quarter. Corient Private Wealth LLC now owns 63,200 shares of the company’s stock worth $135,000 after acquiring an additional 20,000 shares during the last quarter. 75.20% of the stock is currently owned by institutional investors.

About Seer

Seer, Inc is a life sciences company focused on pioneering next-generation proteomics, the large-scale study of proteins and their functions in complex biological systems. By leveraging proprietary nanoparticle-based technology, Seer’s platform enables high-throughput, unbiased protein analysis from biological samples, addressing a critical bottleneck in drug discovery, biomarker research and precision medicine.

The company’s flagship Proteograph Product Suite combines engineered nanoparticle assays with advanced mass spectrometry and bioinformatics pipelines to deliver deep proteomic coverage in a scalable workflow.